Physician profile
Celeste Thomas Williams
NPI 1699843136
$69,972.13
in general payments reported to CMS, 2019-2025
21 companies · $13K in 2025
The $13K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $1,299 · 2021: $709 · 2022: $6,860 · 2023: $340 · 2024: $17K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,552 · Travel and Lodging: $3,894 · Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,325.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,551.96 |
| Travel and Lodging | $3,894.39 |
| Food and Beverage | $1,588.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28,845.25 | 2019 | |
| Pfizer INC. | $25,130.82 | 2019-2025 | |
| Analog Devices INC. | $7,500.00 | 2024 | Sensinel Cpm Wearable |
| Astrazeneca Pharmaceuticals LP | $5,333.15 | 2020-2025 | Wainua |
| Abbott Laboratories | $2,531.74 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Alnylam Pharmaceuticals INC. | $147.47 | 2025 | Onpattro |
| Novo Nordisk INC | $123.64 | 2022-2023 | Ozempic |
| Getinge USA Sales, LLC | $100.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $68.40 | 2024-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.51 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $27.84 | 2025 | Assure Wcd |
| Procyrion, INC. | $22.03 | 2021 | |
| Scpharmaceuticals INC. | $19.62 | 2023 | |
| Cordis US Corp. | $19.45 | 2025 | Mynx Control Venous |
| Bridgebio Pharma, INC. | $18.46 | 2025 | Attruby |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $16.93 | 2023 | Inpefa |
| Medtronic, INC. | $15.66 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.